VivoSeq
Musculoskeletal

Osteopenia

22

Pipeline Programs↗

1

Active Trials↗

15

Companies Involved↗

Osteopenia is an emerging landscape with 22 programs across 15 companies. The most active players are Neurim Pharmaceuticals Ltd., Stero Biotechs Ltd., Otsuka. 7 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

81/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1S

Stero Biotechs Ltd.

1 program

Phase 1Otsuka logo

Otsuka

1 program

Phase 2Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3Amgen logo

Amgen

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

22 of 26 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody28%Peptide28%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 27 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed13 · 72%
Terminated2 · 11%
Unknown status1 · 6%
Active, not recruiting1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Melatonin and Osteogenic Loading on Osteopenia
Active, not recruiting·—·Phase 1·NCT04233112·40 enrolled
Treatment of Osteopenia With Melatonin
Completed·UUniversity of Aarhus·N/A·NCT01690000·81 enrolled
Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
Completed·—·Phase 2·NCT00004488·82 enrolled
Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids
Completed·NNancy E. Lane, MD·Phase 1·NCT03197623·58 enrolled
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Completed·Novartis logoNovartis·Phase 3·NCT00132808·581 enrolled
Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
Completed·—·N/A·NCT02652793·31 enrolled
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Completed·Roche logoRoche·Phase 4·NCT00129623·160 enrolled
Effectiveness of Calcium and Vitamin D, With and Without Collagen Peptide, in Enhancing Bone Mineral Density on Postmenopausal Women With Osteopenia
Completed·FFrontier Medical and Dental College, Abbotabad·N/A·NCT06464718·30 enrolled
Zoledronate for Osteopenia in Pediatric Crohn's
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT00798473·13 enrolled
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
Completed·Roche logoRoche·Phase 3·NCT00545207·150 enrolled
Low and High Doses of Prophylactic Vitamin D in Prevention of Osteopenia of Prematurity
Completed·—·Phase 2·NCT04768439·80 enrolled
Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.
Completed·Pfizer logoPfizer·Phase 1·NCT01293487·68 enrolled
Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia
Completed·YYonsei University·Phase 4·NCT05386784·112 enrolled
Effects of Different Vibration Applications on Bone Turnover Markers and Functionality After Total Knee Arthroplasty in Women With Osteopenia: A Randomized Controlled Trial
Completed·IIstinye University·Preclinical·NCT06988033·48 enrolled
CBD in Postmenopausal Women With Osteopenia
Terminated·CCanopy Growth Corporation·Phase 1·NCT05317013·2 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)